Tardive Dyskinesia

Ingrezza ™ (valbenazine)

Drug UPDATES: INGREZZA ™ (valbenazine) capsules
[Drug information / PDF] REVIEW PACKAGE INSERT FOR POSSIBLE UPDATES
PACKAGE INSERT -Dosing: Click (+) next to Dosage and Administration section (drug info link)
BOXED WARNING:

Initial U.S. Approval: 2017

Mechanism of Action:
The mechanism of action of valbenazine in the treatment of tardive dyskinesia is unknown, but is thought to be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.

INDICATIONS AND USAGE:
INGREZZA is a vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia.

DOSAGE AND ADMINISTRATION:
See package insert for additional instructions - PDF
The initial dose is 40 mg once daily. After one week, increase the dose to the recommended dose of 80 mg once daily. (2.1)
Can be taken with or without food. (2.1)
The recommended dose for patients with moderate or severe hepatic impairment is 40 mg once daily. (2.2)
Consider dose reduction based on tolerability in known CYP2D6 poor metabolizers. (2.2)

HOW SUPPLIED:
Capsules: 40 mg.

®

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.